Oxaliplatin for injection

This product is a new platinum derivative, the central platinum atom is surrounded by oxalic acid and 1.2-diaminocyclohexane, in a trans conformation, and is a stereoisomer. Like other platinum derivatives, oxaliplatin acts on DNA by producing alkylated conjugates, forming intra-chain and inter-chain crosslinks, thereby inhibiting DNA synthesis and replication. Oxaliplatin binds to DNA rapidly, taking up to 15 minutes, while cisplatin binds to DNA in two phases, including a delayed phase after 48 hours. One hour after administration in the human body, its presence can be shown by measuring adducts in white blood cells. DNA synthesis during replication, subsequent DNA separation, RNA and cell protein synthesis are all inhibited. Oxaliplatin treatment is effective in some cell lines that are resistant to cisplatin.

The main ingredient of this product is oxaliplatin. Its chemical name is: (1R-trans)-(1,2-cyclohexanediamine-N,N)[oxalate (Z-)-O,O]platinum.

It can be used alone or in combination with fluorouracil for patients with colorectal cancer metastasis who have failed treatment with fluorouracil.

When used alone or in combination, the recommended dose is 130 mg/m2, added to 250-500 ml of 5% glucose solution and infused for 2-6 hours. When no major toxicity occurs, the drug is administered once every 3 weeks (21 days). Dose adjustment should be based on safety, especially neurological safety.

1. The main adverse reactions in hematology are: anemia, leukopenia, granulocytopenia and thrombocytopenia. 2. The main adverse reactions in non-hematology are: nausea, vomiting, diarrhea. 3. Nervous system: The main manifestation is peripheral neuritis, sometimes there may be spasms and sensory disorders around the mouth, upper respiratory tract and upper digestive tract.

1. It is contraindicated for those who are allergic to platinum derivatives. 2. It should be used with caution during pregnancy and lactation.

This trial has not been conducted and there are no reliable references.

Sealed and stored below 25°C.

50mg

Yangtze River Pharmaceutical (Group) Co., Ltd.

• Founded in:

  2001-03-27

• Address:

  No. 1, South Yangtze River Road, Taizhou

• Tax NO.:

  913212007286987632

• Registered Funds:

  133 million yuan

• Website:

  Log in to view

• Email:

  Log in to view